Advertisement
LetterLetter to the Editor

Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures

Manoli Vourvahis, Lynn McFadyen, Jayvant Heera and Andrew Clark
Drug Metabolism and Disposition May 2015, 43 (5) 771-772; DOI: https://doi.org/10.1124/dmd.115.063321
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

LetterLetter to the Editor

Maraviroc and CYP3A5 Genotype

Manoli Vourvahis, Lynn McFadyen, Jayvant Heera and Andrew Clark
Drug Metabolism and Disposition May 1, 2015, 43 (5) 771-772; DOI: https://doi.org/10.1124/dmd.115.063321
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement